Skip to main content

Beam Therapeutics Inc.

corporate_fare Company Profile

Beam Therapeutics Inc.

BEAM·NASDAQ·Life Sciences·CIK 0001745999

We are a biotechnology company focused on developing precision genetic medicines. Our platform integrates gene editing and delivery technologies with internal manufacturing. Our core technology is proprietary base editing, which aims to precisely target a single base in the genome without creating a double-stranded break in the DNA. This method uses a chemical reaction to achieve precise, predictable, and efficient genetic outcomes at the targeted sequence. Our proprietary base editors consist of two main components: a CRISPR protein bound to a guide RNA, modified to avoid double-stranded breaks, and a base editing enzyme, such as a deaminase, which performs the chemical modification of the target DNA base. We believe this design offers a more precise and efficient edit compared to traditional gene editing methods. We are also developing various delivery modalities, including both ex vivo and in vivo approaches, tailored to specific tissue types. This combination of base editing and tissue-specific delivery forms a targeted, efficient, precise, and versatile gene editing system capable of gene correction, gene silencing, gene activation, gene modification, and/or simultaneous multiplex editing of several genes. Our objective is to advance a broad portfolio of base editing programs against distinct, genetically validated editing targets and to expand the reach of our programs through an innovative platform business model.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for BEAM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 9/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for BEAM spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Beam's Risto-cel Clears Pivotal Sickle Cell Trial, BLA Filing Set for Year-End
  • Beam Q3 Loss Widens to $134.4M; $1.0B Cash Funds Runway Into Mid-2029
  • Beam Therapeutics Posts $1.28 Per-Share Loss for Third Quarter
  • Beam's BEAM-301 Shows Proof of Concept in GSDIa, Restoring Glucose Production
  • Beam Therapeutics Slides 9% as BEAM-302 Data Fails to Impress

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$139.74M
Net Income
-$79.99M
Diluted EPS
-$0.81
Op. Cash Flow
-$345.1M
Free Cash Flow
-$360.05M
Operating Income
-$383.69M
Cash & Equivalents
$294.94M
Debt / Equity
0.00×
Net Margin
-57.2%
Shares Outstanding
101.75M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-065194

Short Interest & Short Volume

13.69 days to cover

FINRA reported short interest of 26,082,937 shares in BEAM as of the October 30, 2026 settlement, a 0.6% decrease from the prior period — about 13.7 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of BEAM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)26,082,937 shares as of October 30, 2026
Change vs prior period▼ 0.6%
Days to cover13.69 at avg daily volume of 1,904,581
Daily short volume (FINRA facilities)52.2% of 1,333,200 shares on November 20, 2026
5-day average short volume58.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$21.66 +3.65% today
52-week range · as of 2026-11-03 $20.23 – $38.26
Market cap
$2.16B
Volume
3.9M (1.7× avg)
3-mo avg 2.2M
Live data · 2026-11-21 23:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BEAM - Latest Insights

BEAM
Nov 10, 2026, 7:03 AM EST
Source: Reuters
Importance Score:
9
Updated Nov 10, 11:57 AM ET — Beam shares fell more than 10% Tuesday despite the positive BEACON readout; UBS reiterated Hold with a $28 target, noting investor focus re…
Price at Filing: $27.40
Real-time Price: $21.66 info
Change: -$5.74 (-21%) info
Market Cap: $2.163B info
BEAM
Nov 03, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.31
Real-time Price: $21.66 info
Change: -$3.65 (-14%) info
Market Cap: $2.163B info
BEAM
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.87
Real-time Price: $21.66 info
Change: -$4.21 (-16%) info
Market Cap: $2.163B info
BEAM
Oct 13, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.47
Real-time Price: $21.66 info
Change: -$3.81 (-15%) info
Market Cap: $2.163B info
BEAM
Sep 08, 2026, 3:24 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.94
Real-time Price: $21.66 info
Change: -$5.27 (-20%) info
Market Cap: $2.163B info
BEAM
Sep 08, 2026, 9:22 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $25.95
Real-time Price: $21.66 info
Change: -$4.28 (-17%) info
Market Cap: $2.163B info
BEAM
Aug 04, 2026, 7:13 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $25.50
Real-time Price: $21.66 info
Change: -$3.84 (-15%) info
Market Cap: $2.163B info
BEAM
Aug 04, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.50
Real-time Price: $21.66 info
Change: -$3.84 (-15%) info
Market Cap: $2.163B info
BEAM
Jun 18, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $32.71
Real-time Price: $21.66 info
Change: -$11.05 (-34%) info
Market Cap: $2.163B info
BEAM
May 07, 2026, 7:22 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $32.12
Real-time Price: $21.66 info
Change: -$10.46 (-33%) info
Market Cap: $2.163B info
BEAM
May 07, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.12
Real-time Price: $21.66 info
Change: -$10.46 (-33%) info
Market Cap: $2.163B info
BEAM
May 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $32.12
Real-time Price: $21.66 info
Change: -$10.46 (-33%) info
Market Cap: $2.163B info
BEAM
Mar 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $26.37
Real-time Price: $21.66 info
Change: -$4.71 (-18%) info
Market Cap: $2.163B info
BEAM
Mar 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.80
Real-time Price: $21.66 info
Change: -$4.14 (-16%) info
Market Cap: $2.163B info
BEAM
Feb 24, 2026, 7:10 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $29.53
Real-time Price: $21.66 info
Change: -$7.87 (-27%) info
Market Cap: $2.163B info
BEAM
Feb 24, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.53
Real-time Price: $21.66 info
Change: -$7.87 (-27%) info
Market Cap: $2.163B info
BEAM
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.16
Real-time Price: $21.66 info
Change: -$7.50 (-26%) info
Market Cap: $2.163B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets